Hold LIN: Await 200 SMA test at $472.90 or 50 SMA reclaim above $511 before adding; $465 close invalidation shifts to Underweight
Maintain existing LIN exposure with no new adds at $490. The structural quality arguments (28% operating margins, $8.1B backlog, $7.4B annual capital return) are valid but already priced at 31.6x trailing P/E without transformation catalyst. Corrected trade plan: entry $478-485 with stop at $465 (fixing inverted original plan with entry $470/stop $472.90). Await 200 SMA test at $472.90 with volume >3M for 10-15% tactical add, or 50 SMA reclaim above $511 for full conviction add. Hard invalidation at $465 close shifts to Underweight with next support $440-460. Hedge existing positions via collar (sell $515 calls, buy $470 puts). Bounded tactical engagement through next earnings cycle and CPI/PCE resolution.
| Position | Action |
|---|---|
| Successful 200 SMA test at $472.90 with bullish reversal on volume >3M shares | Add 10-15% tactical position (single-confirmation framework per 8/7 LIN lesson) |
| Both 200 SMA hold AND 50 SMA reclaim above $511 confirmed | Consider larger position increase with full conviction |
| Close below $465 on volume >3.5M shares (200 SMA fails) | Shift to Underweight, trim exposure; next support at $440-460 |
Linde is a high-quality industrial gas franchise experiencing a sentiment-driven selloff on excellent fundamentals, with structural semiconductor tailwinds and a record backlog providing multi-year revenue visibility.
| Indicator | Value | Signal |
|---|---|---|
| Close | $490.53 | neutral |
| 10 EMA | $493.47 | bullish |
| 50 SMA | $511.56 | bearish |
| 200 SMA | $472.90 | bullish |
| RSI (14) | 40.39 | neutral |
| MACD | -7.59 | bearish |
| MACD Signal | -6.57 | bearish |
| MACD Histogram | -1.03 | bearish |
| Bollinger Middle (20 SMA) | $501.40 | neutral |
| Bollinger Upper | $526.89 | neutral |
| Bollinger Lower | $475.92 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 50 SMA reclaimed above $511 with confirmed breakout
Then: Entry confirmation; confirms basing pattern resolution to upside
↩ rebuts: “Bear concern that competitors like Air Products could pressure margins”
EV: +20-25% (bull case total return including buybacks) · concedes: The 50 SMA at $511.56 is real resistance; failure to reclaim it would be a warning; Q2 gross margin compressed 170 bps (cost of revenue grew 12.8% vs sales growth of 9.3%); Helium supply disruptions and LinCare healthcare restructuring are legitimate headwinds being managed; UK recession odds at 18% create some EMEA exposure risk
Linde is a wonderful company but a terrible stock setup at 31.6x P/E with 2.09 PEG, compressing FCF, 39% CapEx surge, $6.4B net debt increase in 18 months, and technical breakdown just 3.7% above 200 SMA support.
EV: Bear target ~$431 (12% decline from $490.53); realistic downside -15-20% to -$460
→ vs neutral: Missing the structural re-rating opportunity from Phoenix semiconductor deal and Taiwan JV as direct AI infrastructure capex plays
→ vs conservative: Waiting for 200 SMA confirmation at $472.90 is mechanically inverted—entry already set at $470 with ATR of $10.69 leaves insufficient cushion
→ vs conservative: Valuation argument ignores 28% operating margins, 18%+ ROE, negative working capital structure, and seven and a half billion dollars annual capital return
→ vs conservative: HOLD leaves asymmetric upside on table; measured move to 50 SMA at $511 and full retracement to $548+ represents the opportunity cost the cautious playbook never accounts for
| neutral |
| ATR (14) | $10.69 | neutral |
Support: 466.88 · 472.9 · 475.92 | Resistance: 501.4 · 514 · 526.89
LIN is at a technical inflection point following a late-July breakdown. The long-term uptrend remains intact above the 200 SMA ($472.90), but the medium-term trend is bearish with price $21 below the 50 SMA ($511.56). Momentum indicators show deceleration: RSI recovered from oversold (30.16 on 7/31) to 40.39 but stalled in low-40s, while MACD (-7.59) is deeply negative but histogram is narrowing from -2.62 to -1.03. Volatility is elevated with ATR at $10.69 (spiked to $12.82 during breakdown). No death cross yet (50 SMA still above 200 SMA), but the gap is narrowing. Traders are advised to wait for a confirmed reclaim of $501.40 (20 SMA) with supportive RSI/MACD signals before initiating new long positions, with $472.90 as the critical structural support level.
Market Cap
$226.1B
P/E (TTM)
31.63x
Forward P/E
25.04x
PEG Ratio
2.09
P/B
5.88x
EV/EBITDA
~18.0x
Dividend Yield
1.30%
Beta
0.726
52-Week Range
$387.78 – $548.20
50-Day MA
$511.80
200-Day MA
$475.20
Revenue (TTM)
$35.45B
Gross Margin
48.4%
Operating Margin
28.1%
Net Margin
20.4%
EBITDA (TTM)
$13.82B
Net Income (TTM)
$7.24B
Diluted EPS (TTM)
$15.51
Forward EPS
$19.59
ROE
18.40%
ROA
7.16%
Revenue YoY (Q2 2026)
+9.3%
EPS YoY (Q2 2026)
+11.3%
5Y Revenue CAGR
~1.5%
5Y EPS CAGR
~17%
Operating CF (2025)
$10.35B
Free Cash Flow (TTM)
$4.16B
CapEx (2025)
$5.26B
Total Debt
$28.01B
Cash & Equivalents
$4.90B
Net Debt
$23.12B
Stockholders' Equity
$39.08B
Total Assets
$88.35B
Debt/Equity
0.72x
Net Debt/EBITDA
1.67x
Annual Dividends
~$2.81B
Annual Buybacks
~$4.60B
Total Capital Return
~$7.4B/yr
Share Count Reduction
6%
Treasury Stock
$12.9B
Q2 2026 Revenue
$9.29B
Q2 2026 Operating Income
$2.54B
Q2 2026 Diluted EPS
$4.15
Q2 2026 Free Cash Flow
$833M
Strengths
Concerns
Linde plc is the world's largest industrial gases company with a $226.1B market cap trading at premium multiples (31.6x P/E, 5.9x P/B) that reflect its best-in-class 28.1% operating margin and defensive profile (0.73 beta). Q2 2026 demonstrated accelerating momentum with revenue up 9.3% YoY and EPS up 11.3%, while the company generates ~$5B annual FCF supporting ~$7.4B of capital returns through dividends and buybacks. Elevated CapEx ($5.26B in 2025, +17% YoY) signals investment in clean hydrogen and semiconductor gases but pressures near-term free cash flow, with valuation leaving limited room for execution miscues.
Macro: U.S. stocks down for second consecutive session (Aug 11) as investors de-risk into CPI release; markets pricing 86% probability of no Fed rate cuts in 2026 (slightly more dovish by -3.0pp week-over-week); U.S. recession odds at 8% and falling — a tailwind for domestic backlog conversion; UK recession odds at 18% (+5.5pp) and Japan at 36% (+7.5pp) rising; defensive quality names expected to hold better than cyclicals in cautious pre-CPI tape.